Published in Medicine and Law Weekly, September 23rd, 2005
Sara Cunningham, CEO of Benitec, Ltd., stated, "There has never been a doubt in our minds about the validity of our patents. In conjunction with the recent successful resolution of our contract dispute with Promega, this result will allow us to broadly license our issued patent estate and use any ensuing revenue to focus on developing RNA interference (RNAi) based therapeutics for the treatment of infectious diseases.
"RNAi, as with any groundbreaking technology, has been the subject of enormous legal scrutiny. As...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.